United States Dollar: Fed focus and Warsh risk – BBH
Brown Brothers Harriman’s Elias Haddad notes Brent Oil is testing its 200-day moving average while the Dollar consolidates after giving back more than half of its post-May payrolls gains. The bank says a hawkish Fed hold would support a firmer Dollar, but warns Chair Kevin Warsh’s stance on guidance and inflation could unsettle Dollar bulls.
Fed hold and Warsh communication risks
"Brent crude oil prices continued to slide, testing important technical support at the 200-day moving average of $78.46/bbl. USD is consolidating just above this week’s low, after surrendering more than half of its post May non-farm payrolls gains. A hawkish Fed hold will support a firmer USD, but Fed Chair Kevin Warsh risks spoiling the dollar bull party."
"The center of gravity on the FOMC has shifted from an easing to a neutral bias as US labor demand has improved and inflation has moved up. As such, the focus will be on the degree of hawkishness and whether it validates Fed funds futures pricing for a 25bps hike by year end or leans against it. The clearest signal will come from the dot plot, which is expected to shift from implying a 25bps cut in 2026 to a median projection consistent with a 25bps hike."
"Warsh does not believe in forward guidance, so expect him to downplay the importance of the SEP and dot plots. Warsh also said he preferred to follow “trimmed averages” inflation as opposed to core PCE. The Dallas Fed trimmed mean PCE and the Cleveland Fed 16% trimmed mean CPI are currently below core PCE, implying room for the Fed to loosen policy."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.
